TSX-V TZR.V last: 0.01 vol: 10000 OTCQX TCRRF last: 0.01 vol: 20000

management & directors

Dan Carriere
Chairman of the Board

During the past 30 years, Mr. Carriere has been instrumental in the development and financing of private and public companies that include being a co-founder and Director of ID Biomedical Corp. a start-up that ultimately sold to Glaxo Smith Klein for $1.7 Billion in 2005. Mr. Carriere was also a founding partner of Corriente Resources Inc. from 1992 until the sale of Corriente to CRCC-Tongguan Investment (Canada) Co., Ltd. in 2010 for $780 million. Dan has been Chairman of Terrace since its inception as an oil & gas developer in 2011.

Dave Gibbs
President and Chief Executive Officer, Director

Mr. Gibbs, (BSME Ga Tech 1975) has held executive and senior management positions in several successful independent oil companies, including roles on the senior management team of Superior Oil through its merger with Mobil, the largest transaction in US history at the time ($7 billion) and later participated in the leveraged buyout and ultimate monetization of Union Texas Petroleum with KKR ($2 billion). As CEO of TDC Energy, Dave also built a highly successful offshore Gulf of Mexico development company from 1992 to its merger in 2005. Dave has been President of Terrace since its inception as an oil & gas developer in 2011.

William McCartney
Director, Audit Committee Chairman

Mr. McCartney received a Bachelor of Arts from Simon Fraser University in 1978 and has been a member of the Institute of Chartered Accountants of British Columbia since 1980. Since 1990, Mr. McCartney has been the President of Pemcorp Management Inc. He is a present or past director of: Mercer International Inc., Sunward Resources Corp., Newstrike Capital Inc., Exeter Resource Corp. and Dynasty Metals & Mining Inc. among others.

Ken Shannon

Mr. Shannon received a B.Sc. and M.Sc. in Geology at the University of B.C. and has been involved in the junior resource sector for over thirty years. He has participated in the grass roots discovery of over 30 Billion pounds of copper in Argentina and Ecuador as well as managing work on feasibility and pre-feasibility studies for various commodities in Bolivia, Ecuador and British Columbia. As CEO of Corriente Resources, and other companies he has raised over $200 Million for mining exploration and development. In 2010, Corriente was sold to CRCC-Tongguan Investment (Canada) Co., Ltd. (owned jointly by Tongling Nonferrous Metals Group Holdings Co., Ltd. and China Railway Construction Corporation Limited) for approximately $780 million. Ken is currently President of Inca Management, a private management company in Surrey, B.C.

Murray Oliver

Mr. Oliver has a B.A. in economics and over 25 years' experience as a consultant providing corporate finance, restructuring and shareholder communication services to both private and public companies. Mr. Oliver has worked with the Pemcorp Group of Companies since 1995 and has served as Vice President of Business Development since 2000. He is currently a director of Karsten Energy (TSXV:KAY) and Prospero Silver Corp (TSXV:PSL).

Jennie Choboter
Chief Financial Officer

Jennie has over 30 years of extensive international experience in financial management and corporate governance. She has held a number of senior financial management positions in a variety of industries including natural resources, technology, pulp and paper and insurance. Since 1998 she has been providing financial accounting consulting services to public, private and not for profit organizations. Jennie earned a Bachelor of Commerce degree from the University of Calgary and is a Chartered Professional Accountant.

Deborah Cotter
Corporate Secretary

Ms. Cotter served as Corporate Secretary of CRH Medical Corporation from January 2006 until January 2011. Prior to that, Ms. Cotter was Corporate Secretary of ID Biomedical Corporation from January 1999 until December 2005, the time of its takeover offer by Glaxo Smith Kline plc. ID Biomedical grew from an initial $3 million market capitalization to $1.7 billion at the time of its takeover offer from Glaxo Smith Kline plc in 2005.